Viridian Therapeutics, Inc.\DE (VRDN)
Viridian Therapeutics, Inc.\DE on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
18.0M
Short interest
settlement 2026-10-15
8.0
Days to cover
-0.8 days vs prior
52.3%
Short share of volume
2026-11-02
6,593
Fails to deliver
settlement 2026-10-13
Wed 4 Nov
Next earnings
estimated date
-$348K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in VRDN is 18,002,311 shares, down 1,462,940 shares over the last month. Over the last 48 readings it ranged from 7,761,846 shares (13 February 2026) to 19,511,841 shares (31 August 2026). At the reported average volume of 2.2M shares a day that is 8.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/vrdn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 18,002,311 | +0.2% | 2,243,585 | 8.02 |
| 2026-09-30 | 17,965,668 | -7.7% | 2,026,431 | 8.87 |
| 2026-09-15 | 19,465,251 | -0.2% | 1,236,537 | 15.74 |
| 2026-08-31 | 19,511,841 | +2.5% | 1,178,851 | 16.55 |
| 2026-08-14 | 19,026,492 | -1.1% | 2,101,454 | 9.05 |
| 2026-07-31 | 19,234,874 | +1.6% | 1,700,002 | 11.31 |
| 2026-07-15 | 18,923,758 | +9.1% | 1,917,463 | 9.87 |
| 2026-06-30 | 17,342,672 | +15.5% | 3,118,833 | 5.56 |
| 2026-06-15 | 15,020,329 | +2.9% | 1,489,122 | 10.09 |
| 2026-05-29 | 14,597,487 | +2.3% | 1,849,463 | 7.89 |
| 2026-05-15 | 14,266,320 | +23.9% | 4,665,057 | 3.06 |
| 2026-04-30 | 11,512,229 | +8.0% | 1,667,694 | 6.90 |
| 2026-04-15 | 10,655,439 | -1.7% | 4,109,372 | 2.59 |
| 2026-03-31 | 10,843,213 | +31.7% | 2,738,346 | 3.96 |
| 2026-03-13 | 8,233,141 | +5.3% | 1,132,865 | 7.27 |
| 2026-02-27 | 7,819,966 | +0.8% | 1,312,904 | 5.96 |
| 2026-02-13 | 7,761,846 | -2.2% | 1,399,403 | 5.55 |
| 2026-01-30 | 7,937,926 | -2.6% | 1,476,001 | 5.38 |
| 2026-01-15 | 8,148,951 | -6.1% | 1,568,474 | 5.20 |
| 2025-12-31 | 8,681,872 | -4.0% | 1,437,586 | 6.04 |
| 2025-12-15 | 9,040,297 | -1.5% | 1,393,283 | 6.49 |
| 2025-11-28 | 9,174,113 | -3.1% | 1,822,466 | 5.03 |
| 2025-11-14 | 9,472,517 | -3.0% | 2,057,401 | 4.60 |
| 2025-10-31 | 9,762,681 | -2.3% | 1,825,219 | 5.35 |
| 2025-10-15 | 9,986,922 | -2.4% | 849,532 | 11.76 |
| 2025-09-30 | 10,235,828 | -7.0% | 641,896 | 15.95 |
| 2025-09-15 | 11,000,468 | -4.9% | 892,077 | 12.33 |
| 2025-08-29 | 11,571,282 | -1.8% | 848,104 | 13.64 |
| 2025-08-15 | 11,787,624 | +1.0% | 841,330 | 14.01 |
| 2025-07-31 | 11,675,434 | +0.3% | 626,183 | 18.65 |
| 2025-07-15 | 11,639,358 | +8.0% | 748,924 | 15.54 |
| 2025-06-30 | 10,778,607 | -4.9% | 744,992 | 14.47 |
| 2025-06-13 | 11,335,016 | +5.9% | 711,127 | 15.94 |
| 2025-05-30 | 10,702,697 | +1.5% | 809,546 | 13.22 |
| 2025-05-15 | 10,546,849 | +4.2% | 826,055 | 12.77 |
| 2025-04-30 | 10,124,402 | -8.3% | 774,040 | 13.08 |
| 2025-04-15 | 11,043,451 | +8.7% | 1,286,349 | 8.59 |
| 2025-03-31 | 10,159,066 | +1.6% | 762,190 | 13.33 |
| 2025-03-14 | 9,998,425 | +4.5% | 829,414 | 12.05 |
| 2025-02-28 | 9,567,139 | -1.8% | 889,478 | 10.76 |
| 2025-02-14 | 9,740,752 | -10.5% | 1,016,261 | 9.58 |
| 2025-01-31 | 10,881,666 | -6.5% | 924,699 | 11.77 |
| 2025-01-15 | 11,634,941 | -3.5% | 1,596,461 | 7.29 |
| 2024-12-31 | 12,050,989 | +28.8% | 2,249,757 | 5.36 |
| 2024-12-13 | 9,353,713 | +6.9% | 1,076,166 | 8.69 |
| 2024-11-29 | 8,750,391 | -3.8% | 999,985 | 8.75 |
| 2024-11-15 | 9,097,352 | -9.2% | 1,386,669 | 6.56 |
| 2024-10-31 | 10,020,094 | +2.3% | 711,394 | 14.09 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of VRDN volume is 52.3%, up 6.5 points over the last five sessions. Over the last 30 readings it ranged from 34.1% (28 September 2026) to 66.0% (13 October 2026). The latest reading is in line with the 30-session average of 53.7%, on 1.3M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 703K | 1.3M | 52.3% | 0 |
| 2026-10-30 | 428K | 819K | 52.2% | 0 |
| 2026-10-29 | 452K | 899K | 50.3% | 0 |
| 2026-10-28 | 265K | 536K | 49.4% | 0 |
| 2026-10-27 | 547K | 1.1M | 51.8% | 0 |
| 2026-10-26 | 390K | 850K | 45.8% | 0 |
| 2026-10-23 | 214K | 363K | 59.0% | 0 |
| 2026-10-22 | 248K | 508K | 48.8% | 9,211 |
| 2026-10-21 | 478K | 725K | 66.0% | 520 |
| 2026-10-20 | 542K | 837K | 64.8% | 0 |
| 2026-10-19 | 670K | 1.1M | 61.7% | 0 |
| 2026-10-16 | 405K | 758K | 53.4% | 5,677 |
| 2026-10-15 | 456K | 753K | 60.6% | 0 |
| 2026-10-14 | 996K | 2.4M | 42.3% | 158 |
| 2026-10-13 | 583K | 883K | 66.0% | 0 |
| 2026-10-12 | 402K | 769K | 52.3% | 0 |
| 2026-10-09 | 222K | 364K | 61.1% | 0 |
| 2026-10-08 | 347K | 674K | 51.4% | 0 |
| 2026-10-07 | 330K | 566K | 58.2% | 50 |
| 2026-10-06 | 537K | 829K | 64.8% | 0 |
| 2026-10-05 | 555K | 1.2M | 47.1% | 0 |
| 2026-10-02 | 364K | 556K | 65.5% | 0 |
| 2026-10-01 | 602K | 1.1M | 55.9% | 5,330 |
| 2026-09-30 | 240K | 372K | 64.5% | 0 |
| 2026-09-29 | 213K | 426K | 49.9% | 0 |
| 2026-09-28 | 208K | 609K | 34.1% | 0 |
| 2026-09-25 | 392K | 1.1M | 34.6% | 0 |
| 2026-09-24 | 637K | 999K | 63.8% | 0 |
| 2026-09-23 | 719K | 1.5M | 46.6% | 28,501 |
| 2026-09-22 | 227K | 601K | 37.8% | 310 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in VRDN is 6,593 shares, up 2,924 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (29 July 2026) to 51,630 shares (22 September 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 6,593 | $18.30 | $121K |
| 2026-09-30 | 3,669 | $20.00 | $73K |
| 2026-09-25 | 3,490 | $20.66 | $72K |
| 2026-09-24 | 8,507 | $21.43 | $182K |
| 2026-09-22 | 51,630 | $21.58 | $1.1M |
| 2026-09-17 | 1,255 | $22.44 | $28K |
| 2026-09-09 | 4 | $23.17 | $93 |
| 2026-09-02 | 34,891 | $23.03 | $804K |
| 2026-09-01 | 21,100 | $23.16 | $489K |
| 2026-08-26 | 3,561 | $24.18 | $86K |
| 2026-08-24 | 19,375 | $24.29 | $471K |
| 2026-08-14 | 24,114 | $21.99 | $530K |
| 2026-08-13 | 29,810 | $22.88 | $682K |
| 2026-08-12 | 2,862 | $22.97 | $66K |
| 2026-08-06 | 4,474 | $21.07 | $94K |
| 2026-08-05 | 3,765 | $20.84 | $78K |
| 2026-08-04 | 1,649 | $19.31 | $32K |
| 2026-07-29 | 1 | $19.51 | $20 |
| 2026-07-28 | 31 | $19.70 | $611 |
| 2026-07-24 | 291 | $19.26 | $6K |
| 2026-07-20 | 3,105 | $18.03 | $56K |
| 2026-07-17 | 258 | $18.03 | $5K |
| 2026-07-13 | 12 | $19.74 | $237 |
| 2026-07-02 | 22 | $18.48 | $407 |
| 2026-06-30 | 38,807 | $18.79 | $729K |
| 2026-06-29 | 59 | $17.90 | $1K |
| 2026-06-26 | 4,767 | $17.39 | $83K |
| 2026-06-23 | 18,220 | $17.63 | $321K |
| 2026-06-17 | 66 | $15.98 | $1K |
| 2026-06-16 | 105 | $16.30 | $2K |
Insider trades
SEC Form 4, newest first. JSONInsiders at VRDN reported 2 open-market sells worth $348K in the last 90 days and no open-market buys. Latest filing: Tousignant Jennifer (Chief Legal Officer) on 2026-08-19.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-19 | Tousignant Jennifer | Chief Legal Officer | Sell | 10K | $24.50 | $245K | 0 |
| 2026-08-19 | Tousignant Jennifer | Chief Legal Officer | Exercise or conversion | 10K | $14.41 | $144K | 10K |
| 2026-08-19 | Tousignant Jennifer | Chief Legal Officer | Sell | 4K | $24.50 | $103K | 0 |
| 2026-08-14 | Tripuraneni Radhika | Chief Medical Officer | Exercise or conversion | 40K | $13.21 | $528K | 40K |
| 2026-05-11 | Fairmount Healthcare Fund II L.P. | Director,TenPercentOwner | Buy | 1.2M | $17.00 | $20.0M | 5.1M |
| 2026-05-11 | Fairmount Funds Management LLC | Director, 10% owner | Buy | 1.2M | $17.00 | $20.0M | 5.1M |
| 2026-03-03 | Mahoney Stephen F. | President and CEO | Exercise or conversion | 18K | price not stated in the filing | not stated | 41K |
| 2026-03-03 | Mahoney Stephen F. | President and CEO | Tax withholding | 8K | $29.32 | $224K | 33K |
| 2026-03-03 | Beetham Thomas W. | Chief Operating Officer | Tax withholding | 3K | $29.32 | $92K | 13K |
| 2026-03-03 | Beetham Thomas W. | Chief Operating Officer | Exercise or conversion | 9K | price not stated in the filing | not stated | 16K |
| 2026-03-03 | Harmon Seth | Chief Financial Officer | Tax withholding | 2K | $29.32 | $61K | 8K |
| 2026-03-03 | Harmon Seth | Chief Financial Officer | Exercise or conversion | 6K | price not stated in the filing | not stated | 10K |
| 2026-03-03 | Tousignant Jennifer | Chief Legal Officer | Tax withholding | 2K | $29.32 | $51K | 3K |
| 2026-03-03 | Tousignant Jennifer | Chief Legal Officer | Exercise or conversion | 5K | price not stated in the filing | not stated | 5K |
| 2026-03-03 | Mahoney Stephen F. | President and CEO | Tax withholding | 7K | $30.19 | $224K | 33K |
| 2026-03-03 | Tousignant Jennifer | Chief Legal Officer | Tax withholding | 2K | $30.19 | $51K | 3K |
| 2026-03-03 | Beetham Thomas W. | Chief Operating Officer | Tax withholding | 3K | $30.19 | $92K | 13K |
| 2026-03-03 | Harmon Seth | Chief Financial Officer | Tax withholding | 2K | $30.19 | $61K | 8K |
| 2025-12-31 | Tousignant Jennifer | Chief Legal Officer | Sell | 2K | $31.16 | $71K | 0 |
| 2025-10-23 | Fairmount Healthcare Fund II GP LLC | Director,TenPercentOwner | Buy | 455K | $22.00 | $10.0M | 3.9M |
| 2025-10-23 | Fairmount Funds Management LLC | Director, 10% owner | Buy | 455K | $22.00 | $10.0M | 3.9M |
| 2025-06-10 | Fairmount Funds Management LLC | Director,TenPercentOwner | Exercise or conversion | 13K | $12.31 | $154K | 3.5M |
| 2025-06-09 | Fairmount Funds Management LLC | Director,TenPercentOwner | Exercise or conversion | 2K | $7.80 | $12K | 3.4M |
| 2024-09-27 | Mahoney Stephen F. | President and CEO | Buy | 21K | $23.33 | $499K | 21K |
| 2024-09-27 | Beetham Thomas W. | Chief Operating Officer | Buy | 5K | $23.41 | $117K | 6K |
| 2024-09-13 | Fairmount Healthcare Fund II L.P. | Director,TenPercentOwner | Buy | 1.6M | $18.75 | $30.0M | 3.4M |
| 2024-03-28 | Fairmount Healthcare Fund II L.P. | Director,TenPercentOwner | Other transaction | 6K | price not stated in the filing | not stated | 0 |
| 2024-01-22 | Fairmount Healthcare Fund II L.P. | Director,TenPercentOwner,Other | Buy | 476K | $21.00 | $10.0M | 1.8M |
| 2023-06-16 | Meisner Lara | Chief Legal Officer | Exercise or conversion | 27 | $23.03 | $622 | 30K |
| 2023-06-16 | Meisner Lara | Chief Legal Officer | Sell | 27 | $28.35 | $765 | 30K |
| 2023-06-15 | Meisner Lara | Chief Legal Officer | Exercise or conversion | 2K | $23.03 | $52K | 32K |
| 2023-06-15 | Meisner Lara | Chief Legal Officer | Sell | 2K | $28.02 | $64K | 30K |
| 2023-06-06 | Meisner Lara | Chief Legal Officer | Exercise or conversion | 5K | $18.51 | $95K | 35K |
| 2023-06-06 | Meisner Lara | Chief Legal Officer | Sell | 5K | $25.02 | $128K | 30K |
| 2023-06-05 | Meisner Lara | Chief Legal Officer | Exercise or conversion | 499 | $18.51 | $9K | 30K |
| 2023-06-05 | Meisner Lara | Chief Legal Officer | Sell | 499 | $25.03 | $12K | 30K |
| 2023-06-02 | Meisner Lara | Chief Legal Officer | Sell | 2K | $24.21 | $45K | 30K |
| 2023-06-02 | Meisner Lara | Chief Legal Officer | Exercise or conversion | 2K | $14.00 | $26K | 32K |
| 2023-04-12 | Myers Scott Dunseth | Chief Executive Officer | Buy | 4K | $25.37 | $101K | 260K |
| 2023-03-13 | Myers Scott Dunseth | Chief Executive Officer | Buy | 6K | $29.15 | $160K | 256K |
| 2023-03-09 | Meisner Lara | General Counsel and Secretary | Sell | 30K | $29.07 | $871K | 0 |
| 2023-02-06 | Myers Scott Dunseth | Chief Executive Officer | Grant | 250K | $0.00 | $0 | 250K |
| 2023-02-02 | Violin Jonathan | Chief Executive Officer | Sell | 50K | $36.80 | $1.8M | 431K |
| 2023-02-02 | Violin Jonathan | Chief Executive Officer | Exercise or conversion | 50K | $0.15 | $8K | 531K |
| 2023-02-02 | Violin Jonathan | Chief Executive Officer | Sell | 50K | $36.80 | $1.8M | 481K |
| 2023-01-23 | Meisner Lara | General Counsel and Secretary | Exercise or conversion | 2K | $14.00 | $26K | 7K |
| 2023-01-23 | Meisner Lara | General Counsel and Secretary | Sell | 7K | $35.66 | $244K | 0 |
| 2023-01-23 | Meisner Lara | General Counsel and Secretary | Exercise or conversion | 5K | $23.03 | $114K | 5K |
| 2023-01-17 | Katz Barrett | Chief Medical Officer | Sell | 25K | $37.21 | $925K | 0 |
| 2023-01-17 | Katz Barrett | Chief Medical Officer | Exercise or conversion | 25K | $23.03 | $572K | 25K |
| 2023-01-13 | Katz Barrett | Chief Medical Officer | Sell | 4K | $37.01 | $153K | 0 |
| 2023-01-13 | Katz Barrett | Chief Medical Officer | Exercise or conversion | 4K | $23.03 | $96K | 4K |
| 2023-01-10 | Katz Barrett | Chief Medical Officer | Sell | 47K | $35.30 | $1.7M | 0 |
| 2023-01-10 | Katz Barrett | Chief Medical Officer | Exercise or conversion | 47K | $23.03 | $1.1M | 47K |
| 2023-01-09 | Katz Barrett | Chief Medical Officer | Sell | 13K | $33.04 | $417K | 0 |
| 2023-01-09 | Katz Barrett | Chief Medical Officer | Exercise or conversion | 13K | $23.03 | $291K | 13K |
| 2022-12-21 | Meisner Lara | General Counsel and Secretary | Sell | 16K | $29.19 | $477K | 0 |
| 2022-12-21 | Meisner Lara | General Counsel and Secretary | Exercise or conversion | 16K | $23.03 | $376K | 16K |
| 2022-12-20 | Meisner Lara | General Counsel and Secretary | Sell | 600 | $28.07 | $17K | 0 |
| 2022-12-20 | Meisner Lara | General Counsel and Secretary | Exercise or conversion | 600 | $23.03 | $14K | 600 |
| 2022-12-16 | Meisner Lara | General Counsel and Secretary | Sell | 1K | $28.44 | $37K | 0 |
| 2022-12-16 | Meisner Lara | General Counsel and Secretary | Exercise or conversion | 1K | $23.03 | $30K | 1K |
| 2022-12-15 | Meisner Lara | General Counsel and Secretary | Sell | 300 | $28.08 | $8K | 0 |
| 2022-12-15 | Meisner Lara | General Counsel and Secretary | Exercise or conversion | 300 | $23.03 | $7K | 300 |
| 2022-12-14 | Meisner Lara | General Counsel and Secretary | Sell | 16K | $28.12 | $440K | 0 |
| 2022-12-14 | Meisner Lara | General Counsel and Secretary | Exercise or conversion | 16K | $23.03 | $361K | 16K |
| 2022-12-12 | Meisner Lara | General Counsel and Secretary | Exercise or conversion | 600 | $23.03 | $14K | 600 |
| 2022-12-12 | Meisner Lara | General Counsel and Secretary | Sell | 600 | $28.05 | $17K | 0 |
| 2022-11-15 | Meisner Lara | General Counsel and Secretary | Exercise or conversion | 8K | $14.00 | $114K | 8K |
| 2022-11-15 | Meisner Lara | General Counsel and Secretary | Sell | 8K | $22.05 | $179K | 0 |
| 2022-08-17 | Fairmount Healthcare Fund GP LLC | Director,TenPercentOwner | Buy | 426K | $23.50 | $10.0M | 1.4M |
| 2022-06-01 | Violin Jonathan | Chief Executive Officer | Sell | 30K | $12.20 | $366K | 481K |
| 2022-05-02 | Violin Jonathan | Chief Executive Officer | Sell | 30K | $13.04 | $391K | 511K |
| 2022-04-04 | Violin Jonathan | Chief Executive Officer | Sell | 4K | $18.93 | $68K | 541K |
| 2022-04-01 | Violin Jonathan | Chief Executive Officer | Sell | 26K | $18.92 | $499K | 545K |
| 2022-03-02 | Violin Jonathan | Chief Executive Officer | Sell | 11K | $17.36 | $193K | 571K |
| 2022-03-01 | Violin Jonathan | Chief Executive Officer | Sell | 19K | $17.82 | $337K | 582K |
| 2022-02-03 | Violin Jonathan | Chief Executive Officer | Sell | 909 | $19.16 | $17K | 601K |
| 2022-02-02 | Violin Jonathan | Chief Executive Officer | Sell | 12K | $18.47 | $228K | 602K |
| 2022-02-01 | Violin Jonathan | Chief Executive Officer | Sell | 17K | $19.55 | $327K | 614K |
| 2021-12-08 | Violin Jonathan | See Remarks | Conversion | 628K | $0.00 | $0 | 631K |
| 2021-09-23 | Frazier Life Sciences Public Fund, L.P. | TenPercentOwner | Buy | 200K | $11.00 | $2.2M | 1.5M |
| 2021-09-21 | Fairmount Healthcare Fund L.P. | DirectorOther | Buy | 909K | $11.00 | $10.0M | 938K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON6 Form 144 notices on file for VRDN worth $846K at the prices reported; 1 in the last 90 days worth $348K. Latest: Tousignant Jennifer filed on 2026-08-19 to sell 14,212 shares ($348K) from 2026-08-19.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-19 | Tousignant JenniferOfficer | 14K | $348K | 0.013% | 2026-08-19 | Fidelity Brokerage Services LLC |
| 2026-03-04 | Tousignant JenniferOfficer | 2K | $51K | 0.002% | 2026-03-04 | Fidelity Brokerage Services LLC |
| 2026-03-04 | Mahoney Stephen F.Officer, Director | 7K | $224K | 0.007% | 2026-03-04 | Fidelity Brokerage Services LLC |
| 2026-03-04 | Harmon SethOfficer | 2K | $61K | 0.002% | 2026-03-04 | Fidelity Brokerage Services LLC |
| 2026-03-04 | Beetham Thomas W.Officer | 3K | $92K | 0.003% | 2026-03-04 | Fidelity Brokerage Services LLC |
| 2025-12-31 | Tousignant JenniferOfficer | 2K | $71K | 0.002% | 2025-12-31 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON16 holders report 5% or more of VRDN in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is Fairmount Healthcare Fund II GP LLC at 14.0% of the class (17,201,800 shares), filed 2026-05-13 for an event on 2026-05-11.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-20 | 13G | Point72 Asset Management, L.P.partnership | 5.7M | 5.0% | 2026-08-19 |
| 2026-08-20 | 13G | Point72 Capital Advisors, Inc.corporation | 5.7M | 5.0% | 2026-08-19 |
| 2026-08-20 | 13G | Steven A. Cohenindividual | 5.7M | 5.0% | 2026-08-19 |
| 2026-08-14 | 13G/Ano. 2 | Kynam Capital Management, LPinvestment adviser | 0 | 5.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Kynam Capital Management GP, LLCother entity | 0 | 5.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Yue Tangindividual | 0 | 5.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Deep Track Biotechnology Master Fund, Ltd.corporation | 3.6M | 3.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Deep Track Capital, LPinvestment adviser, other entity | 3.6M | 3.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | David Kroinparent holding company, individual | 3.6M | 3.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Senai Asefaw, M.D.individual | 6.7M | 6.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital Advisors GP LLCother entity | 6.7M | 6.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital Advisors LPpartnership | 6.7M | 6.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Paradigm BioCapital International Fund Ltd.corporation | 5.9M | 5.3% | 2026-06-30 |
| 2026-08-14 | 13G | T. Rowe Price Associates, Inc.investment adviser | 5.7M | 5.2% | 2026-06-30 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 6.1M | 5.5% | 2026-06-30 |
| 2026-05-15 | 13G | Bellevue Asset Management AGcorporation | 6.7M | 6.6% | 2026-03-31 |
| 2026-05-15 | 13G | Bellevue Group AGparent holding company, corporation | 6.7M | 6.6% | 2026-03-31 |
| 2026-05-13 | 13D/Ano. 8 | Fairmount Healthcare Fund II GP LLCpartnership | 17.2M | 14.0% | 2026-05-11 |
| 2026-05-13 | 13D/Ano. 8 | Fairmount Funds Management LLCinvestment adviser | 17.2M | 14.0% | 2026-05-11 |
| 2026-03-27 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2025-11-14 | 13G/Ano. 1 | Commodore Capital LPinvestment adviser, partnership | 3.2M | 3.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Commodore Capital Master LPpartnership | 3.2M | 3.9% | 2025-09-30 |
13F holders
Tracked managers holding VRDN at their latest 13F. JSON6 of the 30 tracked managers held VRDN at their latest 13F, $114.1M in total at quarter-end prices. Point72 Asset Management is the largest at $43.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 2.3M | $43.0M | 0.05% | +2.0M |
| Fisher Asset Management | 2026-06-30 | 1.8M | $32.2M | 0.01% | -17K |
| D. E. Shaw & Co. | 2026-06-30 | 1.2M | $21.7M | 0.01% | -80K |
| Renaissance Technologies | 2026-06-30 | 769K | $14.1M | 0.02% | +566K |
| AQR Capital Management | 2026-06-30 | 127K | $2.3M | 0.00% | +107K |
| Citadel Advisors | 2026-06-30 | 41K | $759K | 0.00% | -2.3M |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$276.4M of operating cash flow.
- Equity
- $662.1M
- Total assets
- $1.10B
- Shares outstanding
- 113,292,269
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$127.1M | n/a | n/a |
| Q1 FY 2026 | 2026-03-31 | n/a | -$104.9M | n/a | n/a |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$120.4M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$34.6M | n/a | n/a |
| Q2 FY 2025 | 2025-06-30 | n/a | -$100.7M | n/a | n/a |
| Q1 FY 2025 | 2025-03-31 | n/a | -$86.9M | n/a | n/a |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$79.7M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$76.7M | n/a | -1.15 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$342.6M | -$276.4M | $495K | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$269.9M | -$232.3M | $511K | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$237.7M | -$184.2M | $898K | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$129.9M | -$93.8M | $797K | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$79.4M | -$54.6M | $338K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
Viridian Therapeutics, Inc.\DE in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Viridian Therapeutics, Inc.\DE (VRDN), SEC CIK 1590750, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-19.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-20.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-19.JSON and CSV
- Company record
- EDGAR filing index for CIK 1590750Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of VRDN is sold short?
18,002,311 shares were held short at the 2026-10-15 settlement, 8.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is VRDN's daily short volume?
On 2026-11-02, 703,420 of the 1,343,642 VRDN shares reported to FINRA were sold short, 52.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does VRDN have fails to deliver?
The SEC's latest file shows 6,593 VRDN shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are VRDN insiders buying or selling?
Insiders at VRDN reported 2 open-market sells worth $348K in the last 90 days and no open-market buys. Latest filing: Tousignant Jennifer (Chief Legal Officer) on 2026-08-19.
Have VRDN insiders filed to sell?
6 Form 144 notices on file for VRDN worth $846K at the prices reported; 1 in the last 90 days worth $348K. Latest: Tousignant Jennifer filed on 2026-08-19 to sell 14,212 shares ($348K) from 2026-08-19.
Who owns 5% or more of VRDN?
16 holders report 5% or more of VRDN in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is Fairmount Healthcare Fund II GP LLC at 14.0% of the class (17,201,800 shares), filed 2026-05-13 for an event on 2026-05-11.
What did VRDN report last quarter?
In FY 2025 it generated -$276.4M of operating cash flow.
Which tracked 13F managers own VRDN?
6 of the 30 tracked 13F managers held VRDN shares at their latest filing, $114.1M in all. The largest: Steve Cohen's Point72 Asset Management (2.3M shares, $43.0M), Ken Fisher's Fisher Asset Management (1.8M shares, $32.2M), D. E. Shaw & Co. (1.2M shares, $21.7M), Renaissance Technologies (769K shares, $14.1M), Cliff Asness's AQR Capital Management (127K shares, $2.3M), Ken Griffin's Citadel Advisors (41K shares, $759K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.